Top View
- Role of P2Y Receptors in Platelet Extracellular Vesicle Release
- Adenosine Receptor Agonist HE-NECA Enhances Antithrombotic Activities of Cangrelor and Prasugrel in Vivo by Decreasing of Fibrinogen Density in Thrombus
- Review Article
- Reseptregisteret 2014–2018 the Norwegian Prescription Database 2014–2018
- Effect of GPVI-Fc in Combination with Standard Antiplatelet Drugs and of GPVI-Fc Fused to CD39 on Platelet Thrombus Formation
- DUAL ANTIPLATELET THERAPY: Who, What, When, How Long?
- Microglia and Neuroinflammation: What Place for P2RY12?
- Treatment with Apixaban | Eliquis |
- Effect of Chewing Vs Swallowing Ticagrelor On
- Therapeutic Class Overview Platelet Inhibitors
- P2Y12 Inhibition in Macrophages Reduces Ventricular Arrhythmias in Rats After Myocardial Ischemia-Reperfusion
- (Therapeutic Products) Regulations 2015
- FEP 5 Tier Rx Drug Formulary (607) Standard Option
- Platelet Purinergic Receptors in Thrombosis and Inflammation Gachet, Hechler
- Tenncare Attestation List September 1, 2021
- Downloads/Drugs/.../Guidances/UCM072137.Pdf [Cited 2014 Nov 3]
- Luna Investments
- NVA237 / Glycopyrronium Bromide Multinational, Multi-Database Cohort
- P2Y12 Receptor Modulation of ADP-Evoked Intracellular Ca2+
- The Efficacy and Safety of Cilostazol As an Alternative to Aspirin in Chinese
- 022433Orig1s000
- Platelet Aggregation Inhibitors (PDF)
- What Should Be the Safety Profile of Drug Eluting Stents Suitable for Short DAPT
- Studies of the Interaction of Ticagrelor with the P2Y13 Receptor and with P2Y13-Dependent Pro-Platelet Formation by Human Megakaryocytes
- 204958Orig1s000
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Medication Safety: Switching P2Y12 Inhibitors
- List of Selected Drugs
- First Randomized Human Experience with a Ticagrelor Reversal Agent
- Ticagrelor (Brilinta) for Secondary Prevention of Thrombotic Events
- P2Y Receptor
- Brilique INN-Ticagrelor
- Personalizing Oral Antiplatelet Therapy in PCI
- 510(K) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY
- Ticagrelor (Brilinta)
- Download (Accessed on 8 May 2020)
- Rabbi Eliyahu Shuman Director of Supervision Effective Through 07
- Deprescribing: Antiplatelets (Aspirin, Clopidogrel, Ticagrelor, Dipyridamole and Prasugrel)
- Guidelines for the Management of Anticoagulant Agents
- A New Treatment for Acute Coronary Syndromes Editor By: Horieh Pourmandi, Pharm.D
- Genesis and Characterization of Human Enos-Based Platelet Subpopulations. Implications for Haemostasis and Thrombosis
- BRILINTA (Ticagrelor) 90 Mg Is Supplied As a Round, Biconvex, Yellow, Film-Coated Tablet Marked with a “90” Above “T” on One Side
- Newer Anticoagulants • Describe Tests Which Detect Drug Presence • Describe the Wash-Out Periods • Outline Reversal in Urgent Situations
- Efficacy and Safety of Newer P2Y12 Inhibitors for Acute Coronary
- CONSUMER INFORMATION • You Are Allergic (Hypersensitive) to Ticagrelor Or Any of the Ingredients of BRILINTA
- Platelet Inhibition with Cangrelor and Crushed Ticagrelor in STEMI Patients
- High Platelet Reactivity After Transition from Cangrelor to Ticagrelor in Hypothermic Cardiac Arrest Survivors with ST-Segment Elevation Myocardial Infarction
- P2Y12 Inhibition Beyond Thrombosis: Effects on Inflammation
- Adjunctive Cilostazol to Dual Antiplatelet Therapy to Enhance
- Extracellular Matrix in Development and Disease
- Effective 07-01-2021) the Florida Medicaid Preferred Drug List (PDL